[{"data":1,"prerenderedAt":247},["ShallowReactive",2],{"drug-pramipexole":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":20,"formulations":25,"regimens":63,"contraindications":114,"warnings":115,"renal":123,"monitoring":124,"interactions":125,"review":126,"examples":129,"atc":140,"iran":142,"links":190,"populations":207,"usApproval":242},"pramipexole",1,{"fa":7,"en":8},"پرامی‌پکسول","Pramipexole","nervous-system",{"fa":11,"en":12},"آگونیست دوپامین","Dopamine agonist",[14,17],{"name":15,"market":16},"Mirapex","US",{"name":18,"market":19},"Sifrol","GB",[21,22,23,24],"mirapex","sifrol","سیفرول","پرامیپکسول",[26,40,48,56],{"id":27,"form":28,"route":29,"label":30,"concentration":31,"markets":35,"refs":36},"tab-0-125","tablet","oral","0.125 mg tablet",{"amount":32,"unit":33,"perUnit":28,"scored":34},0.125,"mg",false,[16],[37],{"source":38,"section":39},"fda-pramipexole","3",{"id":41,"form":28,"route":29,"label":42,"concentration":43,"markets":45,"refs":46},"tab-0-25","0.25 mg tablet",{"amount":44,"unit":33,"perUnit":28,"scored":34},0.25,[16],[47],{"source":38,"section":39},{"id":49,"form":28,"route":29,"label":50,"concentration":51,"markets":53,"refs":54},"tab-0-5","0.5 mg tablet",{"amount":52,"unit":33,"perUnit":28,"scored":34},0.5,[16],[55],{"source":38,"section":39},{"id":57,"form":28,"route":29,"label":58,"concentration":59,"markets":60,"refs":61},"tab-1","1 mg tablet",{"amount":5,"unit":33,"perUnit":28,"scored":34},[16],[62],{"source":38,"section":39},[64,89],{"id":65,"disease":66,"label":67,"population":70,"type":74,"unit":33,"dose":75,"refs":76,"limits":79,"notes":82},"rls","restless-legs",{"fa":68,"en":69},"پای بی‌قرار — ۰٫۱۲۵ mg، ۲ تا ۳ ساعت پیش از خواب","Restless legs — 0.125 mg 2–3 h before bedtime",{"minAge":71},{"value":72,"unit":73},18,"year","fixed",{"perDose":32,"dosesPerDay":5},[77],{"source":38,"section":78},"2.3",{"maxPerDay":52,"refs":80},[81],{"source":38,"section":78},[83],{"text":84,"refs":87},{"fa":85,"en":86},"در صورت نیاز هر ۴ تا ۷ روز: ۰٫۲۵ سپس ۰٫۵ mg (با کلیرانس ۲۰ تا ۶۰: هر ۱۴ روز).","If needed every 4–7 days: 0.25 then 0.5 mg (CrCl 20–60: every 14 days).",[88],{"source":38,"section":78},{"id":90,"disease":91,"label":92,"population":95,"type":74,"unit":33,"dose":97,"refs":99,"limits":102,"notes":107},"pd","parkinsons",{"fa":93,"en":94},"پارکینسون — شروع ۰٫۱۲۵ mg سه بار در روز","Parkinson’s — start 0.125 mg three times daily",{"minAge":96},{"value":72,"unit":73},{"perDose":32,"dosesPerDay":98},3,[100],{"source":38,"section":101},"2.2",{"maxPerDay":103,"refs":104},4.5,[105],{"source":38,"section":106},"2",[108],{"text":109,"refs":112},{"fa":110,"en":111},"تیتراسیون تدریجی هر ۵ تا ۷ روز طبق جدول برچسب؛ در نارسایی کلیه کاهش.","Gradual titration every 5–7 days per the label table; reduce in renal impairment.",[113],{"source":38,"section":101},[],[116],{"text":117,"refs":120},{"fa":118,"en":119},"خوابیدن ناگهانی حین فعالیت؛ رفتارهای وسواسی (قمار، خرید، میل جنسی)؛ افت فشار وضعیتی.","Falling asleep during activities; impulse-control behaviours (gambling, shopping, sexual urges); orthostatic hypotension.",[121],{"source":38,"section":122},"5",[],[],[],{"status":127,"reviewer":128,"date":128},"unverified",null,[130,135],{"regimen":65,"formulation":27,"input":131,"expect":134},{"ageYears":132,"weightKg":133},50,75,{"perDose":32,"tabletsPerDoseRounded":5},{"regimen":90,"formulation":27,"input":136,"expect":139},{"ageYears":137,"weightKg":138},65,70,{"perDose":32},[141],"N04BC05",{"status":143,"forms":144,"refs":185},"registered",[145,149,153,157,161,165,169,173,177,181],{"code":146,"en":147,"fa":148},"09238","PRAMIPEXOLE 0.088MG TAB","قرص پرامی‌پکسول ۰٫۰۸۸ میلی‌گرم",{"code":150,"en":151,"fa":152},"06049","PRAMIPEXOLE 0.18MG TAB","قرص پرامی‌پکسول ۰٫۱۸ میلی‌گرم",{"code":154,"en":155,"fa":156},"05450","PRAMIPEXOLE 0.25MG TAB","قرص پرامی‌پکسول ۰٫۲۵ میلی‌گرم",{"code":158,"en":159,"fa":160},"10019","PRAMIPEXOLE 0.35MG TAB","قرص پرامی‌پکسول ۰٫۳۵ میلی‌گرم",{"code":162,"en":163,"fa":164},"17837","PRAMIPEXOLE 0.375MG ER TAB","قرص آهسته‌رهش پرامی‌پکسول ۰٫۳۷۵ میلی‌گرم",{"code":166,"en":167,"fa":168},"17836","PRAMIPEXOLE 0.75MG ER TAB","قرص آهسته‌رهش پرامی‌پکسول ۰٫۷۵ میلی‌گرم",{"code":170,"en":171,"fa":172},"06050","PRAMIPEXOLE 0.7MG TAB","قرص پرامی‌پکسول ۰٫۷ میلی‌گرم",{"code":174,"en":175,"fa":176},"17838","PRAMIPEXOLE 1.5MG ER TAB","قرص آهسته‌رهش پرامی‌پکسول ۱٫۵ میلی‌گرم",{"code":178,"en":179,"fa":180},"06790","PRAMIPEXOLE 1MG TAB","قرص پرامی‌پکسول ۱ میلی‌گرم",{"code":182,"en":183,"fa":184},"50993","PRAMIPEXOLE (AS DIHYDROCHLORIDE) TABLET, EXTENDED RELEASE ORAL 2.1 mg","قرص آهسته‌رهش پرامی‌پکسول (معادل دی‌هیدروکلراید) ۲٫۱ میلی‌گرم",[186],{"source":187,"section":188,"url":189},"darooyab-generic","G-2496\u002FPramipexole","https:\u002F\u002Fwww.darooyab.ir\u002FG-2496\u002FPramipexole",[191,195,199,202,205],{"kind":192,"url":193,"label":194},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=202702","ANDA202702",{"kind":196,"url":197,"label":198},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=fb2260d6-204c-4d25-a331-0f8340d83a6e","FDA Pramipexole",{"kind":200,"url":201,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa697029.html",{"kind":203,"url":204,"label":141},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N04BC05",{"kind":206,"url":189,"label":8},"darooyab",{"pregnancy":208,"lactation":217,"pediatric":225,"geriatric":234},{"level":209,"text":210,"quote":213,"refs":214},"caution",{"fa":211,"en":212},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of pramipexole dihydrochloride tablets in pregnant women.",[215],{"source":38,"section":216},"8.1",{"level":209,"text":218,"quote":221,"refs":222},{"fa":219,"en":220},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of pramipexole in human milk, the effects of pramipexole on the breastfed infant, or the effects of pramipexole on milk production.",[223],{"source":38,"section":224},"8.2",{"level":226,"text":227,"quote":230,"refs":231},"not-established",{"fa":228,"en":229},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of pramipexole dihydrochloride tablet in pediatric patients has not been established.",[232],{"source":38,"section":233},"8.4",{"level":209,"text":235,"quote":238,"refs":239},{"fa":236,"en":237},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Pramipexole total oral clearance is approximately 30% lower in subjects older than 65 years compared with younger subjects, because of a decline in pramipexole renal clearance due to an age-related reduction in renal function.",[240],{"source":38,"section":241},"8.5",{"kind":243,"refs":244,"id":194},"ANDA",[245],{"source":38,"section":246},"SPL approval \u002F marketing category",1792092042951]